Page 112 - GPD-4-1

Gene & Protein in Disease Prognostic role of SIRT1 expression in cancer

Figure 1. Flowchart illustrating the systematic selection process. The screening resulted in 15 eligible records after excluding duplicates, non-English
literature, studies that were not original research, and those with missing details.

Table 1. Characteristics of the studies selected for the meta‑analysis
S. No. Authors Year Country Sample Male Female Cancer type Mean Tumor Detection method Expression
size age stage level
1 Benard et al. 24 2015 Netherlands 254 128 126 CRC 50 I–III Immunohistochemistry Low
2 Li et al. 25 2015 China 75 39 36 Lung cancer 59 I–III & IV Immunohistochemistry High
3 Grbesa et al. 26 2015 Spain 105 93 12 Lung cancer 63 I–IV Immunohistochemistry High
4 Zhang et al. 27 2015 China 50 32 18 CRC 60 I–IV Immunohistochemistry High
5 Teramae et al. 28 2015 Japan 62 N/A 62 Uterine cancer 70 III Immunohistochemistry High
6 Shuang et al. 11 2015 China 63 N/A 63 Ovarian cancer 63 I–IV Immunohistochemistry Low
7 Qiu et al. 29 2016 China 96 75 21 Gastric cancer 60 I–III & IV Immunohistochemistry High
8 Szász et al. 30 2016 Hungary 1065 566 244 Gastric cancer N/A I–IV Immunohistochemistry High
9 Chung et al. 31 2016 South Korea 344 N/A 344 Breast cancer N/A N/A Immunohistochemistry Low
10 Jeh et al. 32 2017 South Korea 119 74 28 Renal cell 59 I Immunohistochemistry Low
carcinoma
11 Mvunta et al. 33 2017 Japan 68 N/A 68 Ovarian cancer 50 III–IV Immunohistochemistry High
12 Gharabaghi et al. 34 2018 Iran 40 N/A N/A Lung cancer N/A I–III Immunohistochemistry High
13 Tan et al. 35 2020 China 530 344 186 Renal cell 60 I–III & IV Gene set enrichment Low
carcinoma analysis
14 Beyer et al. 36 2020 Germany 65 N/A 65 Uterine cancer 64 I–IV Immunohistochemistry High
15 Chen et al. 37 2022 Germany 123 N/A 123 Ovarian cancer 59 I–IV Immunohistochemistry High
Abbreviations: CRC: Colorectal cancer; N/A: Not available.

Volume 4 Issue 1 (2025) 4 doi: 10.36922/gpd.4294